Rchr
J-GLOBAL ID：200901017961111941
Update date: Mar. 30, 2024
Takamune Nobutoki
タカムネ ノブトキ | Takamune Nobutoki
Affiliation and department：
Research field (1)：
Pharmaceuticals - health and biochemistry
Research theme for competitive and other funds (20)：
- 2022 - 2025 Development of novel HIV-1 capsid (CA) inhibitors, and determination regarding novel mechanism of CA uncoating
- 2019 - 2022 Development of basic technology for creating mucosal vaccines using unique medium-chain fatty acids secreted by worker bees
- 2018 - 2021 Fundamental study of NER mechanism aiming to develop a novel HIV therapy in next generation
- 2015 - 2018 Investigation of novel expression mechanism of HIV pathogenic protein to develop the next generation HIV therapy
- 2015 - 2018 Prevention of a virus propagation based on cellular factors controlling HIV infection
- 2015 - 2017 Development and application of M-cell targeting new adjuvant for mucosal immunization
- 2012 - 2015 Study to develop novel anti-HIV strategy targeting to weak point of HIV life cycle
- 2012 - 2015 Exploration of cellular host factor required for HIV-1 infection and approaches to overcome multi-drug resistant HIV-1
- 2010 - 2011 New strategy for inhibition of HIV replication by targeting to NMT1 without appearance of drug resistant virus
- 2009 - 2011 Development of the next generation of AIDS vaccine candidates based on the immune response of HIV-resistant individuals.
- 2008 - 2009 Strategy for inhibition of HIV-1 replication without appearance of drug resistant virus and attenuation of the virus
- 2004 - 2006 Development of HIV-1 coreceptor-based HIV /AIDS defense vaccine
- 2004 - 2005 HIV-1コレセプターの特殊立体構造に対する分子認識自己抗体誘導によるエイズ制御
- 2004 - 2004 ヒト型HIV感染防御抗体・ヒト型エイズ発症防止抗体の創製のための生化学的基礎研究
- 2003 - 2003 HIV-1コレセプターの特殊立体構造に対する分子認識自己抗体誘導によるエイズ制御
- 2002 - 2003 HIV-1感染細胞が誘導する神経細胞死のプロテオーム解析
- 2002 - 2002 HIV-1コレセプターの特殊構造に対する立体特異的自己抗体誘導によるエイズ制御
- 2001 - 2001 耐性ウイルスに有効な抗HIV薬及びコレセプターを基礎にした感染防御法の開発
- 2000 - 2000 耐性ウイルスに有効な抗HIV薬及びコレセプターを基礎にしたワクチンの開発
- 1999 - 2000 DISCOVERY OF SUICIDE PEPTIDE-INHIBITOR OF HIV-1 PROTEASE
Show all
Papers (58)：
-
Tomofumi Nakamura, Mayu Okumura, Nobutoki Takamune, Tatsunori Hirotsu, Masaharu Sugiura, Junichiro Yasunaga, Hirotomo Nakata. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity. PNAS nexus. 2024. 3. 1. pgad446
-
鍬田 伸好, 辻 耕平, 林 宏典, 石井 貴大, 小早川 拓也, 中野 堅太, 服部 真一朗, 岸本 直樹, 高宗 暢暁, 青木 宏美, et al. 抗SARS-CoV-2メインプロテアーゼ阻害剤の創薬研究開発. 日本エイズ学会誌. 2023. 25. 4. 428-428
-
中村 朋文, 奥村 真由, 高宗 暢暁, 弘津 辰徳, 杉浦 正晴, 安永 純一朗, 中田 浩智. 1,3,4-oxadiazole環を有するRaltegravirは強酸性下で加水分解され、抗HIV活性が低下する. 日本エイズ学会誌. 2023. 25. 4. 480-480
-
Manabu Aoki, Hiromi Aoki-Ogata, Haydar Bulut, Hironori Hayashi, Nobutoki Takamune, Naoki Kishimoto, Hiroki Tanaka, Nobuyo Higashi-Kuwata, Shin-Ichiro Hattori, Debananda Das, et al. GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants. Science advances. 2023. 9. 28. eadg2955
-
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, et al. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023. 14. 1. 1076-1076
ｍore...
MISC (3)：
Professional career (1)：
Return to Previous Page
